UNSPSC 51183302: Saxagliptin

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8I7IO46IVQ. European Medicines Agency schedules Saxagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25220. Saxagliptin generally arises in the molecular formula C18H25N3O2.

The term SAXAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations, for tariff and trade purposes, schedule saxagliptin under HS 29339990 and SITC 51577. Saxagliptin bears US NLM identifiers UMLS ID C1611934 and NCI Concept Code C75983. SMILES: OC12C3CC(CC(C1)(CC3)C(N)C(=O)N1C3C(C3)CC1C#N)C2.

UNSPSC 51183302 Saxagliptin is a Commodity code that captures manufacturers' supply of branded and generic diabetes medications to state and local government health systems, correctional facilities, and public health programs through authorized pharmaceutical wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent buyer, procuring generic multi-source pharmaceuticals and over-the-counter products on behalf of participating state and local entities across multiple states including Oregon. Vendors supplying under this code must maintain current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, establish pricing through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and submit detailed product data keyed to National Drug Codes, SKUs, and packaging configurations. Manufacturers typically offer pricing models including flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures, with mandatory insurance coverage including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability per occurrence.

MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts effective July 1, 2026, for a two-year term with optional extensions. Evaluation emphasizes price competitiveness (75 percent weight), with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee on all contract purchases. Products must be available in the marketplace by May 15, 2026, and carry minimum six-month shelf life from manufacture. The solicitation covers multi-state activity spanning Minnesota and Oregon but does not disclose specific contract values or budget allocations. Performance penalties range from $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines.